NEW BRUNSWICK, N.J.—Johnson & Johnson (NYSE: JNJ) reported Tuesday that sales in its third quarter rose 10.3 percent to $19.7 billion, while sales in the U.S. market increased 9.7 percent in the period. On an “operational” basis, J&J’s sales rose 9.5 percent, according to the company’s announcement.

Alex Gorsky, J&J’s chairman and chief executive officer, said the accelerated growth in the third quarter was “driven by the strong performance of our pharmaceutical business, and augmented by Actelion and other recent acquisitions across the enterprise that will continue to fuel growth.” (In the third quarter, J&J also acquired the contact lens subscription service Sightbox Inc. and TearScience Inc., which manufactures products dedicated to treating meibomian gland dysfunction).

Net earnings and diluted earnings per share for the third quarter of 2017 were $3.8 billion and $1.37, respectively.

Within the vision care segment of its business, J&J reported that third-quarter sales of contact lenses and “other” related products rose 8.3 percent to $800 million (a 9.1 percent increase on an operational basis), driven in part by the performance of Oasys 1-Day and Oasys 1-Day for Astigmatism. The U.S. portion of the contact lens business reported sales of $302 million, a 9 percent increase compared with $277 million in the year-ago period.

International sales of contact lenses totaled $498 million in the quarter, which represented an increase of 9.1 percent on an operational basis compared with the year-ago third quarter.

In its earnings announcement, J&J also noted that it is raising its sales guidance for 2017 to a range of $76.1 billion to $76.5 billion, and raising its adjusted earnings guidance for the year to a range of $7.25 to $7.30 per share.